Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 2, 2026, 4:06 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Placebo Injection Clear all
Completed Phase 3 Interventional Results available

Trial of Microplasmin Intravitreal Injection for Non-Surgical Treatment of Focal Vitreomacular Adhesion. The MIVI-TRUST (TG-MV-007) Trial.

NCT00798317
View directory record Official record
Conditions
Vitreomacular Adhesion
Interventions
Ocriplasmin 125µg, Placebo
Drug
Lead sponsor
ThromboGenics
Industry
Eligibility
18 Years and older
Enrollment
326 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
20
States / cities
Campbell, California • San Francisco, California • Santa Barbara, California + 17 more
Source: ClinicalTrials.gov public record
Updated Dec 16, 2014 · Synced Sep 2, 2026, 4:06 PM EDT
Completed Phase 3 Interventional Results available

A Study Comparing Different Dosing Regimens of Ixekizumab (LY2439821) in Participants With Moderate to Severe Plaque Psoriasis

NCT02513550
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
Ixekizumab, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
1,257 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
59
States / cities
Birmingham, Alabama • Anaheim, California • Beverly Hills, California + 52 more
Source: ClinicalTrials.gov public record
Updated Jun 16, 2020 · Synced Sep 2, 2026, 4:06 PM EDT
Completed Phase 2 Interventional

Safety and Biologic Activity Study of Gevokizumab to Treat Erosive Osteoarthritis of the Hand

NCT01882491
View directory record Official record
Conditions
Osteoarthritis
Interventions
Placebo, gevokizumab
Drug
Lead sponsor
XOMA (US) LLC
Industry
Eligibility
18 Years and older
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
23
States / cities
Huntsville, Alabama • Tucson, Arizona • Roseville, California + 20 more
Source: ClinicalTrials.gov public record
Updated Mar 3, 2014 · Synced Sep 2, 2026, 4:06 PM EDT
Terminated Early Phase 1 Interventional

PCSK9 Inhibition in Patients With Symptomatic Intracranial Atherosclerosis

NCT03507374
View directory record Official record
Conditions
Stroke, Intracranial Atherosclerosis, Intraplaque Hemorrhage
Interventions
Alirocumab, Placebo
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Apr 20, 2020 · Synced Sep 2, 2026, 4:06 PM EDT
Recruiting Phase 3 Interventional

Lumbar Steroid Use in Patients Undergoing Posterior Lumbar Decompression

NCT05058287
View directory record Official record
Conditions
Opioid Use, Lumbar Spinal Stenosis, Pain, Postoperative, Pain, Back
Interventions
Depo-Medrol 40Mg/Ml Suspension for Injection, Placebo
Drug
Lead sponsor
Hospital for Special Surgery, New York
Other
Eligibility
18 Years to 85 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 27, 2026 · Synced Sep 2, 2026, 4:06 PM EDT
Completed Phase 2 Interventional Results available

Fasitibant Intra-articular Injection in Patients With Symptomatic Osteoarthritis of the Knee

NCT02205814
View directory record Official record
Conditions
Knee Osteoarthritis
Interventions
Fasitibant- low dose, Fasitibant- intermediate dose, Fasitibant- high dose, Placebo comparator
Drug
Lead sponsor
Menarini Group
Industry
Eligibility
40 Years to 80 Years
Enrollment
436 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
9
States / cities
Tucson, Arizona • Englewood, Colorado • DeLand, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2015 · Synced Sep 2, 2026, 4:06 PM EDT
Active, not recruiting Phase 3 Interventional Results available

A Study of Guselkumab in Participants With Active Psoriatic Arthritis

NCT04882098
View directory record Official record
Conditions
Arthritis, Psoriatic
Interventions
Guselkumab, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
1,054 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
23
States / cities
Birmingham, Alabama • Flagstaff, Arizona • Glendale, Arizona + 20 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Sep 2, 2026, 4:06 PM EDT
Terminated Phase 2 Interventional Results available

HepTcell Immunotherapy in Patients With Inactive Chronic Hepatitis B (CHB)

NCT04684914
View directory record Official record
Conditions
Hepatitis B, Chronic
Interventions
HepTcell, Placebo
Biological · Drug
Lead sponsor
Altimmune, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
5
States / cities
Garden Grove, California • Redwood City, California • San Jose, California + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 7, 2025 · Synced Sep 2, 2026, 4:06 PM EDT
Recruiting Phase 2 Interventional

Apimostinel + Automated Neurocognitive Training for Depression

NCT06400121
View directory record Official record
Conditions
Depression
Interventions
Apimostinel Infusion, Intravenous, Cognitive Training, Sham Training, Isotonic Solution, Intravenous
Drug · Behavioral
Lead sponsor
Rebecca Price
Other
Eligibility
18 Years to 60 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 9, 2026 · Synced Sep 2, 2026, 4:06 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluation of the Safety and Immune Response to an Investigational Dengue Type 1 Vaccine

NCT01084291
View directory record Official record
Conditions
Dengue Virus
Interventions
Investigational Vaccine for DEN1, Placebo injection
Biological · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
2
States / cities
Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Jan 2, 2013 · Synced Sep 2, 2026, 4:06 PM EDT
Not yet recruiting Early Phase 1 Interventional

hCG Treatment for Rehabilitation From a TBI

NCT07557615
View directory record Official record
Conditions
Traumatic Brain Injury
Interventions
Ovidrel, Placebo
Drug · Other
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 65 Years · Male only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Sep 2, 2026, 4:06 PM EDT
Active, not recruiting Phase 2 Interventional

Study to Evaluate Tulisokibart for Hidradenitis Suppurativa (MK-7240-012)

NCT06956235
View directory record Official record
Conditions
Hidradenitis Suppurativa
Interventions
Tulisokibart, Placebo
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 75 Years
Enrollment
149 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
19
States / cities
Birmingham, Alabama • Phoenix, Arizona • Rogers, Arkansas + 16 more
Source: ClinicalTrials.gov public record
Updated Aug 24, 2026 · Synced Sep 2, 2026, 4:06 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Efficacy of Micro-fragmented Adipose Tissue Injection for Knee Osteoarthritis.

NCT03379168
View directory record Official record
Conditions
Knee Osteoarthritis
Interventions
Microfragmented Adipose Tissue (Lipogems), Corticosteroid injection, Saline
Device · Drug
Lead sponsor
Dustin L. Richter, MD
Other
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2023
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Feb 12, 2025 · Synced Sep 2, 2026, 4:06 PM EDT
Completed Phase 3 Interventional Results available

Trial to Confirm the Clinical Efficacy and Safety of Dasiglucagon in the Treatment of Hypoglycemia in Subjects With T1DM

NCT03688711
View directory record Official record
Conditions
Hypoglycemia, Diabetes Mellitus, Type 1
Interventions
Dasiglucagon, Placebo
Drug
Lead sponsor
Zealand Pharma
Industry
Eligibility
18 Years to 75 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
3
States / cities
Chula Vista, California • Escondido, California • Renton, Washington
Source: ClinicalTrials.gov public record
Updated May 18, 2021 · Synced Sep 2, 2026, 4:06 PM EDT
Completed Phase 2 Interventional Results available

Cockroach Immunotherapy in Children and Adolescents

NCT03541187
View directory record Official record
Conditions
Persistent Asthma
Interventions
German cockroach allergenic extract, Placebo for German cockroach allergenic extract
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
8 Years to 17 Years
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
11
States / cities
Aurora, Colorado • Washington D.C., District of Columbia • Chicago, Illinois + 7 more
Source: ClinicalTrials.gov public record
Updated May 21, 2023 · Synced Sep 2, 2026, 4:06 PM EDT
Terminated Not applicable Interventional

The Comparison of Semiconductor Embedded Therapeutic Arm Sleeves for the Treatment of ECRB Tendinopathy

NCT06846593
View directory record Official record
Conditions
ECRB Tendinopathy
Interventions
Semiconductor Embedded Therapeutic Arm Sleeves, Placebo Arm Sleeves, Platelet-Rich Plasma with Adipose Stem Cell (PRP+ASC) Injections
Device · Other
Lead sponsor
INCREDIWEAR HOLDINGS, INC.
Industry
Eligibility
18 Years to 65 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Chesterfield, Missouri
Source: ClinicalTrials.gov public record
Updated May 21, 2026 · Synced Sep 2, 2026, 4:06 PM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers Results available

The Impact of Parathyroid Hormone (PTH) on Craniofacial Osseous Regeneration in Bone

NCT01279187
View directory record Official record
Conditions
Implant
Interventions
Teriparatide, Placebo
Drug
Lead sponsor
University of Michigan
Other
Eligibility
30 Years to 85 Years
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2015
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Feb 6, 2018 · Synced Sep 2, 2026, 4:06 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effects of TT301 on Cytokine Levels Post Endotoxin Challenge

NCT01357421
View directory record Official record
Conditions
Traumatic Brain Injury
Interventions
TT301, Placebo
Drug
Lead sponsor
OPKO Health, Inc.
Industry
Eligibility
18 Years to 40 Years · Male only
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 5, 2013 · Synced Sep 2, 2026, 4:06 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety, Tolerability, and Immunogenicity of CRV-101 in Healthy Adult Subjects

NCT03820414
View directory record Official record
Conditions
Herpes Zoster, Varicella Zoster
Interventions
CRV 101, Placebo
Biological
Lead sponsor
Curevo Inc
Industry
Eligibility
18 Years to 49 Years
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Feb 10, 2021 · Synced Sep 2, 2026, 4:06 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of LY3015014 in Otherwise Healthy Participants With High Low-density Lipoprotein (LDL) Cholesterol

NCT01618916
View directory record Official record
Conditions
Healthy Volunteers
Interventions
LY3015014, Placebo
Drug · Other
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
51 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
2
States / cities
Honolulu, Hawaii • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Mar 14, 2019 · Synced Sep 2, 2026, 4:06 PM EDT
Completed Phase 3 Interventional Results available

A Study of Icatibant in Patients With Acute Attacks of Hereditary Angioedema (FAST-3)

NCT00912093
View directory record Official record
Conditions
Hereditary Angioedema
Interventions
Icatibant, Placebo
Drug
Lead sponsor
Shire
Industry
Eligibility
18 Years and older
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
39
States / cities
Alabaster, Alabama • Birmingham, Alabama • Scottsdale, Arizona + 35 more
Source: ClinicalTrials.gov public record
Updated Jun 10, 2021 · Synced Sep 2, 2026, 4:06 PM EDT
Completed Not applicable Interventional Results available

Leptin for Abnormal Lipid Kinetics in HIV Lipodystrophy Syndrome

NCT01511016
View directory record Official record
Conditions
HIV Lipodystrophy
Interventions
Human recombinant leptin ("metreleptin"), Placebo
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years to 64 Years · Male only
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2011
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 26, 2016 · Synced Sep 2, 2026, 4:06 PM EDT
Active, not recruiting Phase 4 Interventional

Benralizumab Airway Remodeling Study in Severe Eosinophilic Asthmatics

NCT03953300
View directory record Official record
Conditions
Asthma
Interventions
Benralizumab, Placebo
Biological
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 70 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
19
States / cities
Birmingham, Alabama • Los Angeles, California • Jacksonville, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Aug 24, 2026 · Synced Sep 2, 2026, 4:06 PM EDT
Recruiting Phase 3 Interventional

Post-Op Pain Control for Prophylactic Intramedullary Nailing.

NCT03823534
View directory record Official record
Conditions
Bone Metastases, Lymphoma, Multiple Myeloma, Opioid Use, Pain
Interventions
Ketorolac, Normal saline, Acetaminophen, Oxycodone Acetaminophen, Morphine, Hydrocodone/Acetaminophen, Oxycodone
Drug
Lead sponsor
St. Louis University
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 21, 2026 · Synced Sep 2, 2026, 4:06 PM EDT